Testing drug safety in people who are pregnant remains a wicked problem, but in the transition toward big data and machine learning, target trials could afford a viable alternative to randomized, controlled trials.
References
Schachter, A. D. & Kohane, I. S. Reprod. Toxicol. 31, 562–569 (2011).
van der Graaf, R. et al. Trials 19, 78 (2018).
Labrecque, J. A. & Swanson, S. A. Eur. J. Epidemiol. 32, 473–475 (2017).
Goldstein, J. A., Bastarache, L. A., Denny, J. C., Pulley, J. M. & Aronoff, D. M. Am. J. Reprod. Immunol. 80, e12971 (2018).
Jerome, R. N. et al. Drug Saf. 41, 303–311 (2018).
Challa, A. P. et al. bioRxiv https://doi.org/10.1101/860627 (2019).
Vernetti, L. et al. Sci. Rep. 7, 1–15 (2017).
Acknowledgements
We thank A. L. Beam for insights on target trials.
Author information
Authors and Affiliations
Contributions
A.P.C., R.R.L., E.S.L., J.A.G. and L.B. drafted this Comment, and J.M.P. and D.M.A. reviewed it for completeness and technical accuracy.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Challa, A.P., Lavieri, R.R., Lippmann, E.S. et al. EHRs could clarify drug safety in pregnant people. Nat Med 26, 820–821 (2020). https://doi.org/10.1038/s41591-020-0925-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-0925-1
- Springer Nature America, Inc.